TY  - JOUR
AU  - Castañeda, Santos
AU  - Casas, Ana
AU  - González-Del-Alba, Aránzazu
AU  - Martínez-Díaz-Guerra, Guillermo
AU  - Nogués, Xavier
AU  - Ojeda Thies, Cristina
AU  - Torregrosa Suau, Óscar
AU  - Rodríguez-Lescure, Álvaro
PY  - 2022
DO  - 10.1007/s12094-022-02872-1
UR  - http://hdl.handle.net/10668/21186
T2  - Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
AB  - Cancer and cancer therapies are a major factor risk for osteoporosis due to bone loss and deterioration of bone microarchitecture. Both factors contribute to a decrease in bone strength and, consequently, increased bone fragility and risk of fracture....
LA  - en
KW  - Antiresorptive agents
KW  - Bone health
KW  - Bone turnover marker
KW  - Cancer
KW  - Diagnosis
KW  - Fragility fracture
KW  - Hormone deprivation therapy
KW  - Hormone therapy
KW  - Osteoporosis
KW  - Bone Density
KW  - Bone Density Conservation Agents
KW  - Breast
KW  - Humans
KW  - Male
KW  - Osteoporosis
KW  - Prostatic Neoplasms
TI  - Bone loss induced by cancer treatments in breast and prostate cancer patients.
TY  - research article
VL  - 24
ER  -